Anavex Life Sciences Corp (AVXL)

[falconer66a]

Carcinogenicity Won't Be A Factor

Tests for carcinogenicity (cancer-causing) and genomic disruptions are standard preclinical tests for proposed new drugs, conducted in a host of organisms. If they haven't been conducted and their results are not available to the FDA, chances of a New Drug Approval are essentially nil.

The Ames Test is the first one, followed by lower animal exposures of the proposed drug, such as tests on Caenorhabditis elegans, a common lab nematode. Then, long-term tests in animals (lab mice, rats). Finally, there is the monitoring of any genomic disruptions (mutations, changes in DNA) in the Phase 1 human trials.

Search all of the literature on blarcamesine in organisms, whether bacteria or animals. I've never seen a single discovery or incident of blarcamesine-induced or -associated carcinogenicity or induction of mutations of any sort. If any are published, please post them.

To the contrary, blarcamesine's favorable modulation of gene expression by its enhancement of chromatin functions tends to obviate against the aberrant mechanisms involved in the genetics of neoplasms (cancers). The FDA review board will be impressed with the absence of evidence or incidents of any carcinogenicity related to blarcamesine.

Actually, many approved drugs are known to be associated with or to induce cancers. Nonetheless, their therapeutic benefits outweigh the infrequent hazards of the drug's cancers.